Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke


Phase N/A Results N/A

Trial Description

Vascular endothelial growth factor (VEGF) and Endostatin (ES) participate angiogenesis after cerebral ischemia. Circulating endothelial progenitor cells (EPCs) also play a crucial role in neovascularization and tissue repair after acute ischemic stroke (AIS). The investigators sought to compare the expression of VEGF and ES in serum and the circulating EPCs in patients after AIS with that of healthy control subjects. The investigators obtained peripheral blood and serum samples from study subjects. EPCs in blood samples from AIS patients and healthy controls were quantified by flow cytometry 1 day, 3 days, 5 days and 7 days after AIS. VEGF and ES were measured by enzyme linked immunosorbent assay at the same time points. The relation between them and the relation of them to prognosis of such patients with acute ischemic stroke were assessed.


Trial Design

  • Observation: Case-Only
  • Perspective: Prospective
  • Sampling: Probability Sample

Trial Population

The patient group comprised twenty male and ten female. Their age ranged from 45 to 74 years. Locations of infarct, as evidenced by radiologic and neurologic symptoms or signs, included the territories of the middle cerebral artery (9 cases), the posterior cerebral artery (8 cases) the anterior cerebral artery (6 cases), vertebrobasilar area (5 cases), and watershed area (2 cases with cortical and subcortical low densities crossing typical vascular territories).


Type Measure Time Frame Safety Issue
Primary Measurement of circulating endothelial progenitor cells 3 months Yes
Secondary Enzyme-linked immunosorbent assay 3 months Yes
Primary Modified Rankin Scale scores 3 months Yes
Secondary Glasgow Outcome Scale scores 3 months Yes

Biospecimen Retention:Samples Without DNA - Peripheral blood samples